Today's data selection: Centrally purchased generic drugs are as effective as original drugs; the price of Japanese tomatoes has risen to 31 yuan per pound

The minimum down payment for commercial loans for first homes in Sanya drops to 25%

The Hainan Branch of the People's Bank of China issued an announcement on the official website on the 17th. After studying the self-regulatory mechanism for market interest rate pricing in Hainan Province, Sanya City's differentiated housing credit policy will be appropriately adjusted: From October 18, households registered in Hainan Province will receive loans to purchase goods in Sanya City. For housing, the minimum down payment ratio for commercial personal housing loans for first homes is adjusted to 25%, and the minimum down payment ratio for commercial loans for second homes is adjusted to 35%.

The announcement clarified that in order to promote the stable and healthy development of the real estate market in Sanya City, in accordance with the regulatory requirements of the Sanya Municipal Government and in conjunction with the real estate market situation in Sanya City, when households registered in Hainan Province take loans to purchase commercial housing in Sanya, the lower limit of the commercial loan interest rate policy for second homes will be adjusted to no. Lower than the market quoted interest rate for loans with corresponding term plus 30 basis points. It is understood that previously, the minimum down payment ratio for commercial loans for households registered in Hainan Province to purchase first homes in Sanya was 30%, and the minimum down payment ratio for commercial loans for second homes was 40%; the lower limit of the interest rate policy for second home commercial loans was no. Lower than the market quoted interest rate for loans with corresponding term plus 60 basis points.

115 countries co-constructing the “Belt and Road” have applied for a total of 253,000 patents in China and obtained 112,000 authorizations.

The "10th Anniversary Patent Statistical Report between China and Countries Co-constructing the "Belt and Road"" released to the media by the State Intellectual Property Office of China on the 17th showed that from 2013 to 2022, a total of 115 countries co-building the "Belt and Road" came to China to submit patent applications. The cumulative number of patent applications and authorizations in China was 253,000 and 112,000 respectively, with average annual growth rates of 5.4% and 9.8% respectively.

At the same time, China has disclosed patent applications in 50 countries and related organizations that are co-building the "Belt and Road". The cumulative number of patent applications disclosed and authorized in the co-building countries is 67,000 and 35,000 respectively, with an average annual growth rate 25.8% and 23.8% respectively.

This latest patent statistics report states that 2023 is the tenth anniversary of the joint construction of the “Belt and Road” initiative. Over the past ten years, the joint construction of the “Belt and Road” has played an important role in promoting open cooperation, innovation linkage, and promoting sustainable development. Economic and trade exchanges between China and the countries jointly building the “Belt and Road” have become increasingly close, and patent activities have become increasingly active. “Belt and Road” patents The "circle of friends" for cooperation continues to expand.

Among the 115 Belt and Road countries that have submitted patent applications in China, the top five in terms of cumulative applications are South Korea, Italy, Singapore, Austria and Luxembourg. The top five together account for 50% of the total number of patent applications from the countries involved in the Belt and Road Initiative. 91.3%.

140,000 real case data: Centrally purchased generic drugs are as effective as original drugs

A study covering 140,000 real case data from 29 medical centers in 16 provinces and cities across the country showed that the clinical efficacy and safety of generic drugs selected by the national centralized procurement are equivalent to those of the original drugs.

As the state organizes the normalization and institutionalization of centralized procurement of drugs, more drugs have been included in the scope of centralized procurement. In order to further study the efficacy and safety of the new batch of drugs selected for centralized procurement, in August 2021, the National Medical Insurance Administration commissioned Xuanwu Hospital to take the lead in launching A real-world evaluation study on the clinical efficacy and safety of the second and third batches of selected drugs.

Since 2018, eight batches of state-organized drug procurement have been carried out, involving 333 kinds of drugs, with a total of more than 216 billion tablets/tubes used across the country. Among the 1,387 selected products in the first eight batches of centralized purchases, generic drugs accounted for 97%. Among the varieties collected through centralized procurement, the proportion of generic drugs used has increased from 70% before centralized procurement to 88%.

This study collected a large sample of clinical case data, including about 140,000 cases. The main information includes diagnosis, prescription, and inspection and test results. It used centralized procurement to directly compare the selected generic drugs with the original drugs. Through case data, we observed the differences between the generic drug group and the original drugs. The health status of patients in the medicine group before, one year after and beyond the implementation of centralized procurement. Research results show that the clinical efficacy and safety of generic drugs selected through centralized procurement are equivalent to those of original drugs.

Another domestically produced 13-valent pneumonia vaccine is close to completing clinical trials. What is the market demand?

Domestic vaccine manufacturer Aimei Vaccine announced on October 17 that the company's Phase III clinical trial of the company's 13-valent pneumococcal polysaccharide conjugate vaccine under development is now nearing completion and will soon enter the statistical unblinding process. If the vaccine is proven effective and approved, it will become the third domestically produced 13-valent pneumonia vaccine approved for marketing.

However, the stock price of Aimi Vaccine was not boosted by the news that day. As of the close, the stock price fell 5.5%. The company's stock price has fallen by about 80% in the past three months. In addition, the China Securities Regulatory Commission’s online service platform disclosed that on October 16, Aimei Vaccine’s A-share listing counseling has been officially accepted by the securities regulatory agency, and the counseling agency is CITIC Securities.

The prospectus document of Aimei Vaccine cited relevant data to show that the market size of China's pneumococcal vaccine has increased from 1.4 billion yuan in 2015 to 8.6 billion yuan in 2021; with the emergence of other new vaccines and the increasing sales of 13-valent pneumonia vaccine products , the total domestic pneumococcal vaccine market size is expected to increase to 43.8 billion yuan in 2030.

The price of tomatoes in Japan has risen to the highest level in ten years, equivalent to about 31 yuan per kilogram

Affected by the persistent high temperatures in many places in Japan this summer, the production of tomatoes and other crops in Japan has recently been reduced. Among them, the price of tomatoes has risen to the highest level in ten years. The reporter learned in a supermarket that a pound of tomatoes sells for 646 yen, which is about 31 yuan. According to Japanese media reports, domestic tomato prices in Japan have increased by more than 60% in two months. Due to insufficient supply, some supermarkets have even begun to restrict the purchase of tomatoes.